Vericel (NASDAQ:VCEL) Releases Earnings Results

Vericel (NASDAQ:VCEL) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07, FiscalAI reports. The firm had revenue of $77.46 million during the quarter, compared to the consensus estimate of $72.70 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.01) earnings per share.

Here are the key takeaways from Vericel’s conference call:

• Record Q2 revenue of $77.5 million increased 22% year over year, driven by strength in both MACI and Burn Care. GAAP net income reached $2.2 million and free cash flow was $14.3 million.
• Vericel raised full-year 2026 revenue guidance to $330 million–$340 million, including higher MACI guidance of $284 million–$290 million and Burn Care guidance of $46 million–$50 million. Management cited strong biopsy and implant growth, commercial execution, and continued MACI Arthro adoption.
• Burn Care revenue rose 22% to approximately $12 million, with Epicel contributing $10.4 million and NexoBrid reaching record revenue of more than $1.5 million. NexoBrid also posted records for ordering centers and hospital unit sales, while BARDA procurement is expected to contribute approximately $3 million in Q3.
• The board authorized Vericel’s first $200 million share repurchase program, supported by approximately $227 million in cash and investments. Management said the program will be balanced with continued investment in internal growth, international expansion, clinical studies, and potential M&A.
• Vericel submitted a U.K. marketing authorization application for MACI and remains on track for a potential 2027 launch, while the MACI ankle MASCOT study began enrolling patients. Management expects the U.K. opportunity to require only a limited commercial investment, but approval and reimbursement remain pending.

Vericel Price Performance

VCEL traded down $1.65 on Friday, hitting $45.96. The company had a trading volume of 521,462 shares, compared to its average volume of 484,960. The stock has a fifty day simple moving average of $41.95 and a 200-day simple moving average of $37.39. The firm has a market capitalization of $2.35 billion, a P/E ratio of 97.79 and a beta of 1.07. Vericel has a 52-week low of $28.95 and a 52-week high of $49.32.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported second-quarter revenue of $77.5 million, up 22% year over year and above the $72.7 million consensus estimate. Earnings were $0.04 per share, beating expectations for a $0.04 loss, while net income reached $2.2 million and free cash flow was $14.3 million. Vericel Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $330 million-$340 million, a range that brackets or modestly exceeds the $331.9 million analyst consensus. MACI revenue growth of 23% was a key contributor to the quarterly performance. Vericel Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The board authorized a $200 million share-repurchase program, which could support earnings per share and signal confidence in Vericel’s cash-generation outlook. Share Repurchase Program Announcement
• Positive Sentiment: Truist reaffirmed its Buy rating and increased its price target to $58 from $54. HC Wainwright also reaffirmed a Buy rating, reinforcing the favorable analyst view. Truist Financial Analyst Rating HC Wainwright Analyst Rating
• Neutral Sentiment: The earnings-call transcript and presentation provide additional operating details but do not indicate a separate material catalyst beyond the reported results and guidance. Q2 2026 Earnings Presentation
• Neutral Sentiment: Analyst sentiment is not unanimous, and Vericel trades at a high earnings multiple, leaving the shares sensitive to any slowdown in growth or weaker-than-expected future results. Conflicting Analyst Sentiment

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on VCEL shares. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. TD Cowen increased their price objective on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday. Truist Financial reiterated a “buy” rating and issued a $58.00 price objective (up from $54.00) on shares of Vericel in a research report on Friday. Weiss Ratings raised Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. Finally, Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vericel currently has a consensus rating of “Hold” and a consensus target price of $58.40.

Insider Transactions at Vericel

In other news, insider Sean C. Flynn sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $40.21, for a total value of $603,150.00. Following the completion of the transaction, the insider owned 1,647 shares of the company’s stock, valued at approximately $66,225.87. This represents a 90.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $44.75, for a total value of $223,750.00. Following the completion of the transaction, the chief financial officer owned 16,009 shares of the company’s stock, valued at approximately $716,402.75. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 52,232 shares of company stock worth $2,304,217 over the last quarter. Insiders own 7.60% of the company’s stock.

Institutional Trading of Vericel

Hedge funds have recently modified their holdings of the business. State Street Corp grew its position in shares of Vericel by 12.7% in the 4th quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company’s stock worth $113,933,000 after buying an additional 356,680 shares during the period. Geode Capital Management LLC boosted its stake in Vericel by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,222,263 shares of the biotechnology company’s stock worth $44,021,000 after acquiring an additional 7,197 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in Vericel by 5.1% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,056,705 shares of the biotechnology company’s stock worth $38,052,000 after acquiring an additional 50,967 shares in the last quarter. Champlain Investment Partners LLC grew its holdings in Vericel by 4.2% in the fourth quarter. Champlain Investment Partners LLC now owns 1,028,847 shares of the biotechnology company’s stock worth $37,049,000 after purchasing an additional 41,248 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Vericel by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 815,620 shares of the biotechnology company’s stock worth $29,372,000 after purchasing an additional 17,765 shares during the period.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.